USP Names “Key” Drug Types, But Leaves Them Out Of Formulary Guidelines
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. Pharmacopeia is dropping recommended drug class subdivisions from its model guidelines in favor of providing CMS with a list of "formulary key drug types" the agency should consider in reviewing plans for the Medicare Rx program